Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models
CONCLUSION: The preclinical study has demonstrated the therapeutic efficacy and mechanism of neoadjuvant combination therapy (nivolumab plus bevacizumab) in treating early TNBC.PMID:38289410 | DOI:10.1007/s12282-024-01543-z
Source: Breast Cancer - Category: Cancer & Oncology Authors: Hongyan Zheng Lihua Wu Jianfeng Chen Na Na Ge Lou Source Type: research